|
INTERACT - An examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes (FP6-LIFESCIHEALTH) (2006-10-01 - 2010-09-30)
(»add to infobox)

|
Nick WAREHAM, Mark Ian MCCARTHY, Edith FESKENS, Jaakko TUOMILEHTO, Elio RIBOLI, Nadia SLIMANI, Yvonne T. VAN DER SCHOUW, H. B. BUENO DE MESQUITA, Salvatore PANICO, Domenico PALLI, Rosario TUMINO, Vittorio KROGH, Carlotta SACERDOTE, Anne TJØNNELAND, Kim OVERVAD, Goran BERGLUND, Göran GÖRAN HALLMANS, Jakob LINSEISEN, Heiner BOEING, Beverley BALKAU, Carlos A. GONZÁLEZ, María-José TORMO, Larraitz LARRAITZ ARRIOLA, Aurelio BARRICARTE, Carmen MARTINEZ-GARCIA, José Ramón QUIRÓS, Ines BARROSO, Oluf PEDERSEN, Ambady RAMACHANDRAN, Markku Heikki Sakari LAAKSO
|
|
UNIVERSITE D'EVRY - VAL D'ESSONNE (FR104 - Essonne) (France), THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), WAGENINGEN UNIVERSITEIT (NL221 - Veluwe) (Netherlands), HELSINGIN YLIOPISTO (FI181 - Uusimaa) (Finland), IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain), INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FR716 - Rhône) (France), UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL310 - Utrecht) (Netherlands), RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (NL310 - Utrecht) (Netherlands), UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II (ITF33 - Napoli) (Italy), CENTRO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA (ITE14 - Firenze) (Italy), ASSOCIAZIONE IBLEA PER LA RICERCA EPIDEMIOLOGICA (ITG18 - Ragusa) (Italy), ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (ITC45 - Milano) (Italy), FONDAZIONE ISTITUTO PER L'INTERSCAMBIO SCIENTIFICO (ISI) (ITC11 - Torino) (Italy), KRAEFTENS BEKAEMPELSE - DANISH CANCER SOCIETY (DK001 - København og Frederiksberg kommuner) (Denmark), AALBORG SYGEHUS (DK00F - Nordjyllands amt) (Denmark), LUNDS UNIVERSITET (SE044 - Skåne län) (Sweden), UMEA UNIVERSITET (SE081 - Västerbottens län) (Sweden), DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany), DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG (DE428 - Potsdam-Mittelmark) (Germany), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (ES511 - Barcelona) (Spain), FUNDACION PARA LA FORMACION E INVES TIGACION SANITARIAS FFIS DE LA REGI ON DE MURCIA (ES620 - Murcia) (Spain), FUNDACION VASCA DE INNOVACION E INV ESTIGATION SANITARIAS (ES213 - Vizcaya) (Spain), INSTITUTO DE SALUD PUBLICA DE NAVARRA (ES220 - Navarra) (Spain), ANDALUSIAN SCHOOL OF PUBLIC HEALTH (ES614 - Granada) (Spain), CONSEJERIA DE SALUD Y SERVICIOS SANITARIOS DEL PRINICPATO DE ASTURIAS (ES120 - Asturias) (Spain), GENOME RESEARCH LTD (UKI11 - Inner London - West) (Great Britain), NOVO NORDISK A/S (DK002 - Københavns amt) (Denmark), DIABETES RESEARCH CENTRE FOUNDATION (NoRegion - NoRegion) (India), KUOPION YLIOPISTO (FI132 - Pohjois-Savo) (Finland) |
| BUDGET: | 11.908.546 € |
| FUNDING: | 10.000.000 € |
| INSTRUMENT: | Integrated Project |
| PROGRAMME: | FP6-LIFESCIHEALTH |
 |
 |
 |
The pattern of variation of the incidence of type 2 diabetes (T2D) suggests that the disorder originates from an interaction between genetic and lifestyle behaviour factors. The InterAct consortium will use observational and trial data to investigate these interactions and explore the implications of these discoveries for preventive action. The observational part of the project is built around a large case-control study nested within an existing multi-national cohort - the EPIC study. The cohort for this project is large, comprising 350,000 participants from 8 European countries. Standardised dietary and physical activity information is available at baseline, and there is an available DNA source and plasma for nutritional biomarkers. Follow up has been completed for an average of 8 years. The collaborators have tested the feasibility and validity of an approach to ascertaining and verifying incident cases of T2D and will amass a case set of 10,000 individuals. A control cohort free of diabetes at baseline and during follow-up is readily available. To ensure efficient and high quality data, DNA extraction and genotyping will be undertaken using centralised high throughput methods. InterAct will undertake a programme of research aimed at describing the association of dietary and nutritional factors with type 2 diabetes, and will describe the association of physical activity with future risk and the ways that these factors interact with obesity. The genetic elements of InterAct will be focused on genes for which there is biological plausibility for interaction. The choice of polymorphisms in candidate genes will be undertaken by a group leading efforts to discover diabetes genes through a variety of approaches including whole genome association studies and through connection to on-going work on nutrigenomics including the NUGO network. We will genotype all 20,000 individuals for genetic variants in 200 key genes and will analyse the data for gene-lifestyle interaction.
|

| PERSONS (30/30) |
 |


Nick WAREHAM (Contact / UNIVERSITE D'EVRY - VAL D'ESSONNE (FR104 - Essonne) (France))

Mark Ian MCCARTHY (Contact / THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain))

Edith FESKENS (Contact / WAGENINGEN UNIVERSITEIT (NL221 - Veluwe) (Netherlands))

Jaakko TUOMILEHTO (Contact / HELSINGIN YLIOPISTO (FI181 - Uusimaa) (Finland))

Elio RIBOLI (Contact / IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (UKI11 - Inner London - West) (Great Britain))

Nadia SLIMANI (Contact / INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FR716 - Rhône) (France))

Yvonne T. VAN DER SCHOUW (Contact / UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL310 - Utrecht) (Netherlands))

H. B. BUENO DE MESQUITA (Contact / RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (NL310 - Utrecht) (Netherlands))

Salvatore PANICO (Contact / UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II (ITF33 - Napoli) (Italy))

Domenico PALLI (Contact / CENTRO PER LO STUDIO E LA PREVENZIONE ONCOLOGICA (ITE14 - Firenze) (Italy))

Rosario TUMINO (Contact / ASSOCIAZIONE IBLEA PER LA RICERCA EPIDEMIOLOGICA (ITG18 - Ragusa) (Italy))

Vittorio KROGH (Contact / ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (ITC45 - Milano) (Italy))

Carlotta SACERDOTE (Contact / FONDAZIONE ISTITUTO PER L'INTERSCAMBIO SCIENTIFICO (ISI) (ITC11 - Torino) (Italy))

Anne TJØNNELAND (Contact / KRAEFTENS BEKAEMPELSE - DANISH CANCER SOCIETY (DK001 - København og Frederiksberg kommuner) (Denmark))

Kim OVERVAD (Contact / AALBORG SYGEHUS (DK00F - Nordjyllands amt) (Denmark))

Goran BERGLUND (Contact / LUNDS UNIVERSITET (SE044 - Skåne län) (Sweden))

Göran GÖRAN HALLMANS (Contact / UMEA UNIVERSITET (SE081 - Västerbottens län) (Sweden))

Jakob LINSEISEN (Contact / DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany))

Heiner BOEING (Contact / DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG (DE428 - Potsdam-Mittelmark) (Germany))

Beverley BALKAU (Contact / INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France))

Carlos A. GONZÁLEZ (Contact / FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (ES511 - Barcelona) (Spain))

María-José TORMO (Contact / FUNDACION PARA LA FORMACION E INVES TIGACION SANITARIAS FFIS DE LA REGI ON DE MURCIA (ES620 - Murcia) (Spain))

Larraitz LARRAITZ ARRIOLA (Contact / FUNDACION VASCA DE INNOVACION E INV ESTIGATION SANITARIAS (ES213 - Vizcaya) (Spain))

Aurelio BARRICARTE (Contact / INSTITUTO DE SALUD PUBLICA DE NAVARRA (ES220 - Navarra) (Spain))

Carmen MARTINEZ-GARCIA (Contact / ANDALUSIAN SCHOOL OF PUBLIC HEALTH (ES614 - Granada) (Spain))

José Ramón QUIRÓS (Contact / CONSEJERIA DE SALUD Y SERVICIOS SANITARIOS DEL PRINICPATO DE ASTURIAS (ES120 - Asturias) (Spain))

Ines BARROSO (Contact / GENOME RESEARCH LTD (UKI11 - Inner London - West) (Great Britain))

Oluf PEDERSEN (Contact / NOVO NORDISK A/S (DK002 - Københavns amt) (Denmark))

Ambady RAMACHANDRAN (Contact / DIABETES RESEARCH CENTRE FOUNDATION (NoRegion - NoRegion) (India))

Markku Heikki Sakari LAAKSO (Contact / KUOPION YLIOPISTO (FI132 - Pohjois-Savo) (Finland))

| RELATED NAVIGATION AREA(S) (1/1) |
 |

Gene-environment interaction on the incidence of type 2 diabetes
|
|
|






|